With regard to the changes of CD44+/CD24− tumour cell populations, the patients with the increase of CD44+/CD24− tumour cell populations tended to have shorter DFS times than the remaining patients irrespective of PST regimen, although they were not statistically significant (Figures 4C–F). This evidence concerns the gene CD44 and neoplasm.